Diagnosing severe falciparum malaria in parasitaemic african children: A prospective evaluation of plasma PfHRP2 measurement by Hendriksen, ICE et al.
Diagnosing Severe Falciparum Malaria in Parasitaemic
African Children: A Prospective Evaluation of Plasma
PfHRP2 Measurement
Ilse C. E. Hendriksen1,2, Juliet Mwanga-Amumpaire3, Lorenz von Seidlein4, GeorgeMtove5, Lisa J. White1,2,
RasaqOlaosebikan6, Sue J. Lee1,2, Antoinette K. Tshefu7, CharlesWoodrow1,2, BenAmos8, CorineKarema9,
Somporn Saiwaew1, Kathryn Maitland10, Ermelinda Gomes11, Wirichada Pan-Ngum1, Samwel Gesase12,
Kamolrat Silamut1, Hugh Reyburn13, Sarah Joseph14, Kesinee Chotivanich1, Caterina I. Fanello1,2,
Nicholas P. J. Day1,2, Nicholas J. White1,2, Arjen M. Dondorp1,2*
1Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand, 2Centre for Tropical Medicine, Churchill Hospital,
University of Oxford, Oxford, United Kingdom, 3Mbarara University of Science and Technology and Epicentre Research Base, Mbarara, Uganda, 4Menzies School of Health
Research, Casuarina, NT, Australia, 5National Institute for Medical Research, Amani Centre, Tanga, Tanzania, 6Medical Research Council Laboratories, Banjul, The Gambia,
7 Kinshasa School of Public Health, Kingasani Research Centre, Kinshasa, Democratic Republic of the Congo, 8 Teule Hospital, Muheza, Tanzania, 9Malaria Control
Program, Ministry of Health, Kigali, Rwanda, 10 Kenya Medical Research Institute (KEMRI)–Wellcome Trust Research Programme, Kilifi, Kenya, 11Hospital Central da Beira,
Beira, Mozambique, 12National Institute for Medical Research, Tanga Medical Research Centre, Tanga, Tanzania, 13 London School of Tropical Medicine & Hygiene,
London, United Kingdom, 14Medical Research Council, London, United Kingdom
Abstract
Background: In African children, distinguishing severe falciparummalaria from other severe febrile illnesses with coincidental
Plasmodium falciparum parasitaemia is a major challenge. P. falciparum histidine-rich protein 2 (PfHRP2) is released by mature
sequestered parasites and can be used to estimate the total parasite burden. We investigated the prognostic significance of
plasma PfHRP2 and used it to estimate the malaria-attributable fraction in African children diagnosed with severe malaria.
Methods and Findings: Admission plasma PfHRP2 was measured prospectively in African children (from Mozambique, The
Gambia, Kenya, Tanzania, Uganda, Rwanda, and the Democratic Republic of the Congo) aged 1 month to 15 years with
severe febrile illness and a positive P. falciparum lactate dehydrogenase (pLDH)-based rapid test in a clinical trial comparing
parenteral artesunate versus quinine (the AQUAMAT trial, ISRCTN 50258054). In 3,826 severely ill children, Plasmadium
falciparum PfHRP2 was higher in patients with coma (p = 0.0209), acidosis (p,0.0001), and severe anaemia (p,0.0001).
Admission geometric mean (95%CI) plasma PfHRP2 was 1,611 (1,350–1,922) ng/mL in fatal cases (n = 381) versus 1,046 (991–
1,104) ng/mL in survivors (n = 3,445, p,0.0001), without differences in parasitaemia as assessed by microscopy. There was a
U-shaped association between log10 plasma PfHRP2 and risk of death. Mortality increased 20% per log10 increase in PfHRP2
above 174 ng/mL (adjusted odds ratio [AOR] 1.21, 95%CI 1.05–1.39, p = 0.009). A mechanistic model assuming a PfHRP2-
independent risk of death in non-malaria illness closely fitted the observed data and showed malaria-attributable mortality
less than 50% with plasma PfHRP2#174 ng/mL. The odds ratio (OR) for death in artesunate versus quinine-treated patients
was 0.61 (95%CI 0.44–0.83, p = 0.0018) in the highest PfHRP2 tertile, whereas there was no difference in the lowest tertile
(OR 1.05; 95%CI 0.69–1.61; p = 0.82). A limitation of the study is that some conclusions are drawn from a mechanistic model,
which is inherently dependent on certain assumptions. However, a sensitivity analysis of the model indicated that the
results were robust to a plausible range of parameter estimates. Further studies are needed to validate our findings.
Conclusions: Plasma PfHRP2 has prognostic significance in African children with severe falciparum malaria and provides a
tool to stratify the risk of ‘‘true’’ severe malaria-attributable disease as opposed to other severe illnesses in parasitaemic
African children.
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Introduction
Severe falciparum malaria in children presents a major
diagnostic challenge in malaria-endemic countries where a high
proportion of children is parasitaemic at any time. A positive
malaria blood smear is therefore not specific for severe malaria,
and neither are clinical signs, which are similar to those of other
severe childhood infections [1–3]. Overdiagnosis of falciparum
malaria in severely ill children is an important problem in sub-
Saharan Africa [4,5]. Misdiagnosis is associated with increased
mortality [6]. Autopsy studies in children dying with ‘‘slide-
positive’’ cerebral malaria show an alternative diagnosis in up to
23% of cases [4]. The central pathological process in severe
falciparum malaria is sequestration of trophozoite- and schizont-
stage–infected erythrocytes in venules and capillaries, which
compromise microcirculatory flow to vital organs [7]. The
circulating young ring-form parasites do not sequester and
therefore do not reflect accurately the sequestered parasite burden.
Thus peripheral parasite counts have weak prognostic significance
[8,9], although this can be improved by assessing the stage of
development of these peripheral blood parasites or counting the
numbers of malaria pigment–containing neutrophils, which
reflects recent schizogony [10,11].
Plasmodium falciparum histidine-rich protein 2 (PfHRP2) is a
water-soluble protein found inside the malaria parasite and host
erythrocyte, and that circulates free or bound to proteins or
antibodies in the plasma compartment [12,13]. PfHRP2 produc-
tion peaks during the trophozoite stage, and approximately 90% is
released during schizont rupture [14]. Since released PfHRP2 is
distributed through the total plasma volume, plasma PfHRP2 can
be considered a measure of total parasite burden of the preceding
48-hour asexual parasite life cycle [14,15]. Studies in Asian adults
have shown a strong correlation between plasma PfHRP2, disease
severity, and outcome [15,16].
In the current study we assessed the prognostic significance of
plasma PfHRP2 in African children with severe malaria and tested
the hypothesis that its assessment could distinguish children with
‘‘true’’ severe malaria, in need of urgent antimalarial treatment,
from those with non-malarial severe febrile illness and coincidental
peripheral blood parasitaemia, in whom alternative diagnoses and
additional treatment need to be considered.
Methods
The study was part of a large multinational trial comparing
quinine and artesunate for the treatment of severe malaria in
African children (‘‘AQUAMAT,’’ ISRCTN 50258054), undertak-
en between October 2005 and July 2010 [17]. Ethics approval was
granted by the Oxford Tropical Research Ethics Committee and
the countries’ ethics review boards. Full details of this trial have
been described elsewhere [17]. In brief, children with signs of
severe malaria confirmed by a positive P. falciparum lactate
dehydrogenase (pLDH)-based rapid diagnostic test were included,
provided their parents or caregivers gave full written informed
consent. Severity was defined by clinical criteria (see Text S1).
Patients were excluded if treated parenterally for .24 hours
before admission. Patients were randomised to treatment with
either parenteral artesunate or quinine. A venous blood sample
was taken for peripheral blood slide, haematocrit (Hct), PfHRP2,
biochemistry, and acid-base parameters (EC8+ cartridge for the i-
STAT handheld blood analyser). Slide reading was performed by
expert microscopists at the Mahidol-Oxford Tropical Medicine
Research Unit, and parasites/ml was calculated from thin film
(count/1,000 RBC6125.66Hct) or thick film (count/200
WBC640) [18,19].
Plasma PfHRP2 was assessed blinded to patient outcomes from
freeze-thawed EDTA plasma samples by a commercial sandwich
ELISA kit (Celisa, Cellabs, Sydney, Australia), according to the
manufacturer’s instructions with minor modifications [15]. Pooled
reference plasma from 20 subjects with P. falciparum parasitaemia
.200,000/ml was calibrated with recombinant PfHRP2 standard
(kindly provided by D. Sullivan, John Hopkins School of Public
Health, Baltimore, Maryland, US) and used to construct standard
curves. Concentrations in duplicate plasma dilutions (1/25 to 1/
3,125 in PBS/0.01%Tween) were determined according to the
linear segment of the standard curve, with re-assay in cases where
duplicates differed by more than 50%. Plasma samples for PfHRP2
were received from nine of the 11 ‘‘AQUAMAT’’ research sites in
seven countries (Mozambique, The Gambia, Kenya, Tanzania,
Uganda, Rwanda, and the Democratic Republic of the Congo).
The study site in Ghana did not collect samples, and the samples
from Nigeria defrosted during transportation.
Individual Patient Estimation of Parasite Burden
Estimation of the total body parasite burden from plasma
PfHRP2 has been described in detail in Asian adults with severe
malaria and requires incorporation of an elimination half-life
estimate [15]. This was assessed separately in African children
because clearance might be dependent on immunity (antibodies
against PfHRP2), which has a higher level in high transmission
settings, and PfHRP2 production is parasite strain dependent [20].
Plasma PfHRP2 half-life was assessed in 30 patients from Tanzania
from samples taken on admission and after 3 and 7 days following
treatment. Separate ethical approval for this sub-study was obtained
from the Ethics Committee of the National Institute for Medical
Research, Tanzania. These data were analysed using WinNonlin
statistical package (Pharsight, Mountain View, California, US).
Individual PfHRP2 concentration-time curves were fitted according
to a first-order elimination model. From this, a mean (95%CI)
plasma elimination half-life (tK) was estimated as 1.10 (0.91 to 1.29)
days, or 0.55 erythrocytic cycles. Half-life was not significantly
different between treatment arms, and was not correlated with renal
function (estimated by blood urea nitrogen [BUN]). A parasite
multiplication factor of 3 immediately before peak parasitaemia was
assumed, based on in-vitro and Saimiri monkey studies of African
parasite strains causing severe malaria [21,22]. Higher multiplica-
tion rates were explored in a sensitivity analysis [23,24]. The
formula for total parasite burden is: Ptot = 7.36PfHRP26(12Hct)6
body weight [kg]61013, with PfHRP2 in g/L [15]. The differences
in the current formula with the one used earlier in adult Asian
patients result from the different estimates for plasma PfHRP2
half-life and parasite multiplication rates. The circulating
parasite burden was calculated from the peripheral blood:
parasites/ml61066blood volume ( = 0.086weight [kg]) [15]. The
sequestration index was calculated as total parasite burden/
circulating burden [25].
Statistical Analysis
Data were analysed with STATA, version 10 (Stata Corp.,
Texas, US). Categorical variables were compared between
survivors and fatal cases with Chi-squared or Fisher’s exact test.
Normally distributed or log10-normalized variables were com-
pared using a Student’s t-test, the remainder by Wilcoxon rank-
sum test. For lowest, middle, and highest tertiles of plasma
PfHRP2, comparisons were made between peripheral blood
parasitaemia, sequestration index, and treatment effect (mortality)
following artesunate versus quinine treatment.
To determine the prognostic significance of plasma PfHRP2, a
logistic regression model was constructed with in-hospital death as
PfHRP2 in Severe P. falciparum Malaria
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the dependent variable and PfHRP2 as the independent variable.
Since the risk of death showed a non-linear association with log10
PfHRP2 (Figure 1, top), both first- and second-degree fractional
polynomial functions were explored to find the optimal fit. A
quadratic polynomial function provided the best fit using the
likelihood ratio test and by comparison of AUCs (areas under the
curve). The regression model was stratified for study site and
adjusted for treatment and other established predictors of death,
including coma, convulsions, prostration, hypoglycaemia, respira-
tory distress, shock (combined compensated and decompensated),
parasitaemia (/mL), haemoglobin (Hb; g/dL), blood urea nitrogen
(BUN; mg/dL), and base excess (BE; mmol/L) [8,9]. Using a
stepwise approach, only covariates that were significant at p,0.01
were retained in the final model. Fit of the final logistic regression
model was confirmed using the Hosmer-Lemeshow goodness-of-fit
test after ordering the data on predicted probabilities and then
regrouping the data into 10 nearly equal-sized groups [26].
Any interaction with transmission intensity regarding associa-
tions between plasma PfHRP2 and survival was checked and
accounted for if significant. Study sites in Mozambique and The
Gambia were defined as low transmission; Rwanda, Tanzania,
and Kenya as intermediate; and study sites in Uganda and the
Democratic Republic of Congo as high transmission.
Modelling Malaria-Attributable Mortality Based on
Plasma PfHRP2
A mechanistic model was constructed to describe the observed
U-shaped relationship between PfHRP2 strata and probability of
in-hospital death (Figure 1, top), making the following assump-
tions: (1) an exponential increase of malaria-attributable mortality
with plasma PfHRP2, which describes the right side of the curve in
Figure 1 (top): Prdeath|malaria =21+exp(k1logPfHRP2k2); (2) a
probability of severe febrile illness due to non-malaria, which
decreased exponentially with increasing logPfHRP2: Prnon-malaria
= exp(2k4logPfHRP2); (3) a risk of death in patients with non-
malaria infection equal to 0.3, independent of plasma PfHRP2:
Prdeath|non-malaria = 0.3 [5,27]; and (4) that 20% of all deaths were
due to non-malaria illness: Deathnon-malaria/Deathtotal = 0.2 [4]. The
number of non-malarial deaths according to PfHRP2 stratum is
then given by:
Deathnon-malaria = Prdeath|non-malaria6Prnon-malaria6Casestotal and
the number of deaths due to malaria by Deathmalaria = Prdeath|malaria
6(12Prnon-malaria)6Casestotal. For more details, see Text S2. The
effects of assumptions 3 and 4 were explored in a sensitivity analysis.
Results
Patient Characteristics
Of the 5,425 children with pLDH-based rapid diagnostic test
RDT confirmed falciparum malaria included in the ‘‘AQUA-
MAT’’ trial, plasma PfHRP2 was measured in 3,826 patients.
PfHRP2 could not be measured in 1,600 (29%) patients because
the sample was either not collected or not received in optimal
condition. Patients without PfHRP2 data did not differ from the
remainder regarding malaria slide positivity rate, geometric mean
parasitaemia, or case fatality rate. Baseline clinical and laboratory
characteristics according to outcome are summarized in Table 1.
Although many clinical and laboratory variables associated with
severity differed between survivors and fatal cases, admission
parasitaemia did not.
Plasma PfHRP2 in Relation to Disease Severity
PfHRP2 was detectable in 3,800/3,826 (99%) patients with
severe malaria. A detectable plasma PfHRP2 (geometric mean,
95% CI, 450 ng/mL, 209 to 966 ng/mL) with a negative blood
slide result (but positive malaria RDT) was found in 36 (0.9%)
children. Geometric mean plasma PfHRP2 (95%CI) in survivors
was 1,046 ng/mL (991 to 1,104 ng/mL) versus 1,611 ng/mL
(1,350 to 1,922 ng/mL) in fatal cases (p,0.0001, Table 2). There
was no heterogeneity by stratification for transmission intensity in
the difference of plasma PfHRP2 concentrations between survivors
and fatal cases (p = 0.1).
Plasma PfHRP2 concentrations in relation to established
features of severe falciparum malaria are summarized in Table 2.
Plasma PfHRP2 was significantly higher in patients with coma,
acidosis, and severe anaemia but not in those with shock.
Estimated Total Body Parasite Burden
Geometric mean (95% CI) PfHRP2-derived total parasite
burden was 7.561011 (7.261011 to 7.961011) parasites/body
(n= 3,800); this was greater in fatal cases (1.261012 [1.061012 to
1.561012], n = 327) than in survivors (7.261011 [6.861011 to
7.661011], n = 3,070, p,0.0001) (Figure 2). In contrast, the total
circulating peripheral blood parasite burden did not differ
significantly between survivors and fatal cases (p = 0.66). The
geometric mean (95%CI) calculated sequestration index, the ratio
of total parasitaemia to circulating parasitaemia was 17 (15 to 18)
in survivors, versus 30 (23 to 40) in fatal cases (p = 0.0001). The
sequestered parasite burden, calculated by subtracting the
circulating parasite burden from the total parasite burden, gave
a negative result in 296/3,397 (8.7%) patients. Excluding these
patients, the geometric mean (95%CI) total sequestered parasite
burden was 7.761011 parasites/body (7.361011 to 8.261011,
n = 3,101). A sensitivity analysis varying the multiplication factor
and PfHRP2 plasma half-life is shown in Text S3.
Plasma PfHRP2 and Risk of Death
There was a U-shaped association between plasma PfHRP2 and
risk of death with a nadir in case fatality rate at a logPfHRP2 of
2.24 ( = 174 ng/mL; Figure 1, top). In an adjusted logistic
regression model, stratified by study site, plasma PfHRP2 was a
strong independent predictor of death. Odds for death were 20%
higher per unit increase in logPfHRP2 (adjusted odds ratio [AOR]
1.21, 95%CI 1.05 to 1.39, p= 0.009) above a threshold
logPfHRP2 value of 2.24 ( = 174 ng/mL). Below this concentra-
tion, risk of death increased with decreasing plasma logPfHRP2
(AOR 2.3, 95%CI 1.1 to 5.0; p= 0.03). The final model was
adjusted for plasma BE, BUN, coma, convulsions, hypoglycaemia,
peripheral blood parasitaemia, and antimalarial treatment (Hos-
mer-Lemeshow p-value for goodness-of-fit = 0.35).
Distinguishing Death Attributable to Severe Malaria from
Death Attributable to Other Causes
High mortality rates were associated with either very low or
very high values of plasma PfHRP2 (Figure 1, top), with the former
presumably resulting from a disease other than malaria (including
sepsis). The observed case fatalities in the lowest PfHRP2 half log
stratum and the higher PfHRP2 strata of $3.5–4.0 were both over
15%. A mechanistic model describing the U-shaped correlation
between logPfHRP2 stratum and risk of death showed a good fit
with the observed data and the statistical model (Figure 1, top).
This model was deconvoluted into two separate functions
corresponding to non-malaria- and malaria-attributable case
fatality rates (Figure 1, bottom). The model showed that below a
plasma logPfHRP2 value of 2.24 ( = 174 ng/mL) (derived from the
nadir in the polynomial logistic regression model), the probability
that death resulted from malaria fell below 50%, corresponding to
PfHRP2 in Severe P. falciparum Malaria
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overall proportions of malaria-attributable severe disease ,90%
(Figure 1, bottom). In the logPfHRP2 stratum of 3 to 3.5 (1,000 to
3,162 ng/mL) and above, the absolute risk of death due to malaria
exceeded 8% with a probability of ‘‘true’’ severe malaria .95%
and a probability that a death was caused by severe malaria.85%
(Figure 1, bottom). For a sensitivity analysis of the mechanistic
model see Text S2.
In patients within the highest PfHRP2 tertile, corresponding to
logPfHRP2 $3.4 (2,300 ng/mL), the odds ratio (OR) for death in
patients treated with artesunate versus quinine was 0.61 (95%CI
Table 2. Plasma PfHRP2 according to clinical and laboratory features of severe malaria.
Parameter Trait n Plasma Pf HRP2a p-Value
Outcome Fatal 381 1,611 (1,350–1,922) ,0.0001
Surviving 3,445 1,046 (991–1,104)
Coma (GCS#10 or BCS#2) Yes 1,230 1,193 (1,079–1,320) 0.0209
No 2,596 1,047 (986–1,111)
Acidosis (BE,28 mmol/L)b Yes 1,383 1,494 (1,382–1,614) ,0.0001
No 1,692 969 (896–1,047)
Severe anaemia (Hb,5 g/dL)b Yes 958 1,585 (1,458–1,722) ,0.0001
No 2,306 1,044 (975–1,118)
Shockc Yes 570 1,193 (1,051–1,355) 0.16
No 3,256 1,075 (1,016–1,138)
BCS, Blantyre coma scale; BE, base excess; GCS, Glasgow coma scale, Hb, haemoglobin.
aData are geometric mean (95% CI).
bBE available for n = 3,075 and Hb available for n = 3,264 due to missing i-STAT values.
cCompensated and decompensated shock combined.
doi:10.1371/journal.pmed.1001297.t002
Table 1. Demographic, clinical, and laboratory characteristics of children diagnosed with severe falciparum malaria according to
outcome.
Characteristic Survivors (n =3,445) Fatal Cases (n =381) p-Value
Female sex, n (%) 1,692 (49%) 188 (49%) 0.93
Age, y (median, IQR) 2.7 (1.5–4) 2.3 (1.4–4) 0.055
Fever before enrolment, d, median (IQR) 3 (2–4) 3 (2–4) 0.54
Coma before enrolment, h, median (IQR) 4 (2–8) 5 (3–8) 0.020
Complications on admission
Coma (GCS,11 or BCS,3), n (%) 983 (29%) 247 (65%) ,0.0001
Convulsions, n (%) 1,176 (34%) 186 (49%) ,0.0001
Severe acidosis (BE,28 mmol/L), n (%) 1,132 (41%) 251 (80%) ,0.0001
Severe anaemia (Hb,5 g/dL), n (%) 841 (29%) 117 (34%) 0.030
Hypoglycaemia, n (%) 317 (9%) 136 (36%) ,0.0001
Respiratory distress, n (%) 466 (14%) 103 (27%) ,0.0001
Shock (compensated & decompensated), n (%) 470 (14%) 100 (26%) ,0.0001
Black water fever, n (%) 126 (4%) 18 (5%) 0.30
Jaundice, n (%) 75 (2%) 16 (4%) 0.014
Hyperparasitaemia, n (%) 778 (25%) 101 (30%) 0.046
Laboratory assessments
P. falciparum slide positive 99% 98% 0.088
Parasitaemia, geometric mean (range) 45,008 (0–1,858,880) 39,589 (0–1,252,227) 0.33
Blood urea nitrogen, mg/dL, mean (SD) 15 (11) 23 (16) 0.0001
Haemoglobin, g/dL, mean (SD) 6.9 (2.8) 6.5 (2.9) 0.015
pH, mean (SD) 7.38 (0.11) 7.24 (0.19) ,0.0001
HCO3, mmol/L, mean (SD) 17.0 (5.4) 11.3 (5.8) ,0.0001
Base excess, mmol/L, mean (SD) 28 (7) 216 (8) 0.0001
BCS, Blantyre coma scale; BE, base excess; GCS, Glasgow coma scale, Hb, haemoglobin.
doi:10.1371/journal.pmed.1001297.t001
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Figure 1. Observed and modelled malaria-attributable mortality and morbidity according to plasma PfHRP2 concentrations. (Top
graph) Observed number of patients (grey bars, n = 3,826) and observed probability of death (squares with 95% CI error bars, n = 381) according to
PfHRP2 half-log10 strata. The statistical polynomial regression model (dashed line) and the mechanistic model (black line) show the probability of
death according to PfHRP2 half-log10 strata. For a detailed description of the mechanistic model see Text S2. (Bottom graph) Malaria-attributable
mortality and morbidity according to plasma PfHRP2 concentrations. The curve derived from the mechanistic model (top) describing the relationship
between log10 plasma PfHRP2 concentration and probability of death has been deconvoluted in two separate functions: (1) Non[en-dash]malaria-
attributable probability of death (dotted line, left axis), which describes the negative exponential probability of dying from non-malaria illness with
increasing plasma PfHRP2 concentrations, at a constant PfHRP2 independent case fatality rate of 30%. (2) Malaria-attributable probability of death
(thin solid line, left axis), which describes the exponential increase in the probability of death with increasing plasma PfHRP2 concentration, a
PfHRP2 in Severe P. falciparum Malaria
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0.44 to 0.83, p= 0.0018). In patients in the lowest PfHRP2 tertile,
there was no difference in mortalities with an OR for death of 1.05
(95%CI 0.69 to 1.61; p = 0.82, Figure 3). The geometric mean
(95%CI) sequestration index, the ratio of total to circulating
parasite numbers was 69.8 (60.8 to 80.1) in patients in the highest
and 4.6 (4.0 to 5.3) in the lowest PfHRP2 tertile (Table 3).
Discussion
This very large prospective study in African children with severe
falciparum malaria shows the strong and independent prognostic
value of admission plasma PfHRP2 concentration, but not the
conventional peripheral blood malaria parasite count. In
addition, plasma PfHRP2 was found to be the best immediate
measure available to distinguish severe disease caused by malaria
from severe febrile illness resulting from another disease with
incidental P. falciparum parasitaemia. Since PfHRP2 is a measure
of total parasite burden, this suggest a critical pathophysiological
role played by sequestered parasites in severe falciparum
malaria. This is supported by studies which have correlated
obstruction of microcirculatory flow in the rectal and retinal
circulations to disease severity and outcome, the strong
prognostic value of metabolic acidosis in severe malaria, and
autopsy studies showing intense sequestration in vital organs
[8,25,28–31].
These results suggest that in areas of moderate or high malaria
transmission where a high proportion of children are parasitaemic,
admission plasma PfHRP2 can differentiate children at highest risk
of death due to severe falciparum malaria from those with likely
alternative causes of severe febrile illness. These findings are
supported by several observations.
Firstly, plasma PfHRP2 derived total parasite numbers
(geometric mean 7.561011/body) are biologically plausible, and
were significantly higher in fatal cases. In contrast, less pathogenic
circulating peripheral blood parasite numbers were not correlated
with a fatal outcome. The calculated sequestration index was 17 in
surviving patients and 30 in non-survivors, which is similar to the
median (IQR) sequestration index of 40 (9.9–273.8) calculated
directly from post-mortem blood vessel counts in 50 Thai and
Vietnamese adults who died from cerebral malaria [25].
Second, the U-shaped curve with a nadir at 174 ng/mL
describing the relationship between PfHRP2 and risk of death fits
with the assumption that with low PfHRP2, death is caused by
non-malarial febrile illnesses (including sepsis) which are indepen-
dent of the low parasite burden, whereas in patients with plasma
PfHRP2 above this nadir the probability of death increases with
PfHRP2, representing ‘‘true’’ severe malaria with increasing
sequestered parasite burdens. The mechanistic model based on
these assumptions had a close fit with the observed data. An
alternative explanation could be the presence of highly virulent
parasite strains causing severe disease independent of a high total
parasite burden. However, this would result in a PfHRP2-
independent mortality at the left side of the curve and cannot
explain the U shape that was actually observed. Assumptions in
constructing the mechanistic model included an alternative cause
measure of total parasite burden, in the patient population with ‘‘true’’ severe malaria. From these deconvoluted functions the proportion of the total
number of deaths attributable to ‘‘true’’ severe malaria was derived according to PfHRP2 half-log10 strata (diamonds and heavy solid line, malaria-
attributable deaths, right axis). Using the ‘‘true’’ severe malaria case fatality rates per PfHRP2 half-log10 strata, the proportion of ‘‘true’’ severe malaria-
attributable cases according to PfHRP2 half-log10 strata was derived (circles and dashed line, malaria-attributable cases).
doi:10.1371/journal.pmed.1001297.g001
Figure 2. Comparison of circulating parasite burden and total
parasite burden between surviving (blue circles, n =3,070) and
fatal (red squares, n=327) cases. Circulating parasite burden was
calculated from the peripheral blood parasitaemia and the total parasite
burden was estimated from plasma PfHRP2, including 3,397 patients
with both detectable PfHRP2 and malaria parasites on the peripheral
blood smear.
doi:10.1371/journal.pmed.1001297.g002
Figure 3. Treatment effect, as odds ratio for death, of
artesunate versus quinine. Effect is measured according to plasma
PfHRP2 tertiles and compared to the overall treatment effect observed
in the AQUAMAT trial [17] in 5,425 African children and in the similar
SEAQUAMAT trial [32] in 1,461 (predominantly) adults in Asia.
doi:10.1371/journal.pmed.1001297.g003
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of death in 20% of patients and a risk of death in non-malaria
disease of 30%, based on published autopsy and clinical
microbiology data [4,27]. However, the conclusions were not
dependent on these assumptions and were robust to the plausible
ranges of values defined for the sensitivity analysis.
Third, the treatment benefit of artesunate over quinine was
absent in patients in the lowest PfHRP2 tertile, and strongest in the
highest tertile (OR 0.61, 95%CI 0.44 to 0.83, p = 0.0018). Since
injectable artesunate can benefit only patients with ‘‘true’’ severe
malaria, this provides strong supportive evidence that patients with
high PfHRP2 do represent this group, and patients with low
PfHRP2 do not. The OR of 0.61 in the highest PfHRP2 tertile is
remarkably close to the OR of 0.60 (95%CI 0.45 to 0.79) reported
in the large SEAQUAMAT trial comparing artesunate with
quinine in the treatment of severe falciparum malaria in 1,461
patients in low-transmission settings in Asia [32]. In these
epidemiological settings incidental peripheral blood malaria
parasitaemia is rare. The diagnosis of severe malaria based on a
peripheral blood slide is therefore highly specific, and so the
treatment effect of artesunate over quinine is undiluted by non-
malarial disease.
Identification of children with slide-positive severe febrile illness
but who do not have severe malaria is important for patient
management, since overdiagnosis of severe malaria is associated
with increased mortality [6]. A low plasma PfHRP2 should
prompt investigation of alternative diagnoses including septicae-
mia, early administration of parenteral broad spectrum antibiotics
(if not already routine), and intensive monitoring. Often antibiotics
are given only after a disappointing clinical response to
antimalarials, which may be too late. High plasma PfHRP2
concentrations should not discourage antibiotic treatment com-
bined with antimalarial treatment, because of the high proportion
of concomitant invasive bacterial disease [2]. Patients with high
plasma PfHRP2, which indicates ‘‘true’’ severe malaria with a
poor prognosis, should be monitored closely, preferentially in a
high-dependency or intensive care unit. As a tool in the design of
clinical trials, plasma PfHRP2 is substantially better than
peripheral blood parasitaemia in assessing the malaria-attributable
fractions and defining the group of patients with ‘‘true’’ severe
malaria and a high risk of death (Figure S3 in Text S4 and [33])
An alternative tool is the presence of malaria retinopathy, which
has been shown to be highly specific for cerebral malaria as
confirmed by post-mortem autopsy [4], although this tool does
require training and skilled ophthalmoscopy [34,35]. It has been
evaluated for cerebral malaria [36,37], whereas many patients
with severe falciparum malaria present with other syndromes [17].
PfHRP2 can be used in both cerebral and severe non-cerebral
malaria. A direct comparison between the two methods is
currently underway. Development of a semi-quantitative rapid
test for the detection of plasma PfHRP2 with carefully chosen
thresholds could be a valuable tool in high transmission settings to
distinguish ‘‘true’’ severe malaria from severe non-malarial febrile
illness. For example, a plasma PfHRP2 concentration of
.1,000 ng/mL (62.1% of cases in our cohort) denotes a
probability .95% of ‘‘true’’ severe malaria with an overall case
fatality rate of 11.6% (95%CI 10.3 to 12.9). Defining populations
with ‘‘true’’ severe malaria and high mortality is thus critical
information for clinicians as well as researchers. In contrast, a
plasma PfHRP2 concentration ,100 ng/mL (8.1% of cases in our
cohort) denotes a probability .15% that severe non-malarial
illness is the cause of illness, warranting additional investigations.
Limitations of this study include the inherent dependency of the
models on certain assumptions. Estimating the total parasite
burden from PfHRP2 is sensitive to the assumed parasite
multiplication factor. In the current study the multiplication rate
was assumed to be 3, based on in vitro data comparing
multiplication rates and multiplication potency of parasites
obtained from African children compared to Asian adults. The
multiplication rate of 8 used in the original model in Asian adults
was based on non-immune adult patient data from the era of
malaria therapy of neurosyphilis, and comparable information is
obviously not available for our patient group. Applying this higher
multiplication rate in this study results in an implausibly high
estimated total parasite burden. In addition to differences in
parasite multiplication rates, the calculated total parasite burden is
dependent on the assumed half-life of plasma PfHRP2, which can
vary between patients, and on the amount of PfHRP2 released per
parasite per cycle, which can vary between strains [15,20]. A
sensitivity analysis of these parameters is shown in Figure S2 in
Text S3. The half-life of plasma PfHRP2 in the current study was
shorter than observed in adult patients in Southeast Asia (mean 1.1
versus 3.7 days) [15]. This is presumably related to the African
setting where malaria transmission is high and immunological
factors including high PfHRP2 antibody titres could increase
plasma clearance of PfHRP2 [38,39]. Since variations in the
model parameter estimates are applied to the entire patient group,
the model renders either pathophysiologically implausible upper
(more parasites than the number of circulating red cells) or lower
limits (fewer total parasites than the calculated circulating
parasitaemia). Actual total parasite numbers can thus be slightly
Table 3. Parasite density, Sequestration Index and Treatment effects of artesunate versus quinine according to PfHRP2 tertiles.
PfHRP2 tertiles{ Low (n=1,115) Middle (n=1,154) High (n=1,128)
Plasma PfHRP2 (n=3,397)
(range, geometric mean, 95%CI)
0 to 829
218 (201–236)
830 to 2,298
1,401 (1,379–1,424)
2,299 to 78,848
4,762 (4,598–4,932)
Parasitaemia (n =3,397)
(geometric mean, 95% CI)
32,934
(28,993 to 37,410)
p,0.0001
60,864
(53,924 to 68,698)
p = 0.041
50,597
(44,463 to 57,577)
Sequestration (n =3,397)
(geometric mean, 95% CI)
4.6
(4.0 to 5.3)
p,0.0001
16.9
(15.0 to 19.2)
p,0.0001
69.8
(60.8 to 80.1)
OR (95% CI) for fatal outcome
artesunate versus quinine
(n =3,826)
1.05
(0.69 to 1.61)
p = 0.82
0.81
(0.54 to 1.22)
p = 0.32
0.61
(0.44 to 0.83)
p = 0.0018
{Tertiles derived from complete PfHRP2 data set (n = 3,826).
doi:10.1371/journal.pmed.1001297.t003
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different from the model estimates. However, differences in the
calculated total parasite burdens between subgroups do not
depend on the choice of these variables, since these variables will
affect this value by the same factor in all subgroups. A recent study
in Papuan children with falciparum malaria did not show a
correlation between PfHRP2 and disease severity [40]. However,
children (n= 220) in this study diagnosed with severe malaria
appeared to be only moderately ill as reflected by the ,1% case
fatality rate and low plasma PfHRP2 values (median 456 ng/mL),
whereas patients in that study considered to have uncomplicated
malaria had lower plasma bicarbonate concentrations as a measure
of acidosis than those with severe malaria. In the present study,
,1% cases had undetectable plasma PfHRP2 concentrations,
despite presence of P. falciparum on the blood slide. This could have
been caused by genetic variation in PfHRP2 [41], although this
polymorphism is thought not to affect the detection by ELISA
[42,43]. Deletions of the PfHRP2 gene have been reported in field
isolates from the Amazon region and in a single report from sub-
Saharan Africa [44,45]. However, the incidence of this genotype is
thought to be low in parasites causing severe malaria related to
reduced parasite fitness [46,47]. A study sequencing the PfHRP2
gene in parasites from all patients in the current study who had low
plasma PfHRP2 concentrations is underway.
In conclusion, admission plasma PfHRP2 provides a tool in
areas of moderate and high malaria transmission to distinguish
‘‘true’’ severe falciparum malaria from severe febrile illness with
incidental malaria parasitaemia. Plasma PfHRP2 concentrations
are a valuable prognosticator in African children with severe
falciparum malaria.
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Editors’ Summary
Background Malaria is a life-threatening disease caused by
parasites that are transmitted to people through the bites
of infected mosquitoes. In 2010, malaria caused an
estimated 655,000 deaths worldwide, mostly in Africa,
where according to the World Health Organization, one
African child dies every minute from the disease. There are
four Plasmodium parasite species that cause malaria in
humans, with one species, Plasmodium falciparum, causing
the most severe disease. However, diagnosing severe
falciparum malaria in children living in endemic areas is
problematic, as many semi-immune children may have the
malaria parasites in their blood (described as being
parasitaemic) but do not have clinical disease. Therefore, a
positive malaria blood smear may be coincidental and not
be diagnostic of severe malaria, and unfortunately, neither
are the clinical symptoms of severe malaria, such as shock,
acidosis, or coma, which can also be caused by other
childhood infections. For these reasons, the misdiagnosis of
falciparum malaria in severely ill children is an important
problem in sub-Saharan Africa, and may result in unneces-
sary child deaths.
Why Was This Study Done? Previous studies have
suggested that a parasite protein—P. falciparum histidine-
rich protein-2 (PfHRP2)—is a measure of the total number of
parasites in the patient. Unlike the circulating parasites
detected on a blood film, which do not represent the
parasites that get stuck in vital organs, PfHRP2 is distributed
equally through the total blood plasma volume, and so can
be considered a measure of the total parasite burden in the
previous 48 hours. So in this study, the researchers assessed
the prognostic value of plasma PfHRP2 in African children
with severe malaria and whether this protein could distin-
guish children who really do have severe malaria from those
who have severe febrile illness but coincidental parasitaemia,
who may have another infection.
What Did the Researchers Do and Find? The researchers
assessed levels of plasma PfHRP2 in 3,826 out of a possible
5,425 African children who participated in a large multina-
tional trial (in Mozambique, The Gambia, Rwanda, Tanzania,
Kenya, Uganda, and the Democratic Republic of Congo) that
compared the anti-malarial drugs quinine and artesunate for
the treatment of severe malaria. All children had a clinical
diagnosis of severe malaria confirmed by a rapid diagnostic
test, and the researchers used clinical signs to define the
severity of malaria. The researchers assessed the relationship
between plasma PfHRP2 concentrations and risk of death
taking other well established predictors of death, such as
coma, convulsions, hypoglycaemia, respiratory distress, and
shock, into account.
The researchers found that PfHRP2 was detectable in 3,800/
3,826 (99%) children with severe malaria and that the
average plasma PfHRP2 levels was significantly higher in the
381 children who died from malaria than in children who
survived (1,611 ng/mL versus 1,046 ng/mL). Plasma PfHRP2
was also significantly higher in children with severe malaria
signs and symptoms such as coma, acidosis, and severe
anaemia. Importantly, the researchers found that high death
rates were associated with either very low or very high
values of plasma PfHRP2: the odds (chance) of death were
20% higher per unit increase in PfHRP2 above a specific
threshold (174 ng/ml), but below this concentration, the risk
of death increased with decreasing levels, probably because
at lower levels disease was caused by a severe febrile disease
other than malaria, like septicemia. Finally, the researchers
found that in children within the highest PfHRP2 tertile, the
chance of death when treated with the antimalarial drug
artesunate versus quinine was 0.61 but that there was no
difference in death rates in the lowest tertile, which supports
that patients with very low plasma PfHRP2 have a different
severe febrile illness than malaria. The researchers use
mathematical modeling to provide cut-off values for plasma
PfHRP2 denoting the proportion of patients with a diagnosis
other than severe malaria.
What Do These Findings Mean? These findings suggest
that in areas of moderate or high malaria transmission where
a high proportion of children are parasitaemic, plasma
PfHRP2 levels taken on admission to hospital can differen-
tiate children at highest risk of death from severe falciparum
malaria from those likely to have alternative causes of severe
febrile illness. Therefore, plasma PfHRP2 could be considered
a valuable additional diagnostic tool and prognostic indica-
tor in African children with severe falciparum malaria. This
finding is important for clinicians treating children with
severe febrile illnesses in malaria-endemic countries: while
high levels of plasma PfHRP2 is indicative of severe malaria
which needs urgent antimalarial treatment, low levels
suggest that another severe infective disease should be
considered, warranting additional investigations and urgent
treatment with antibiotics.
Additional Information Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001297.
N A previous small study in PLOS ONE explores the
relationship between plasma PfHRP2 and severe malaria
in Tanzanian children
N The WHO website and the website of Malaria No More
have comprehensive information about malaria
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